The XIAP inhibitor AZD5582 improves the treatment effect of microwave ablation on hepatocellular carcinoma DOI Creative Commons
Wenhui Wang, Fu‐Yuan Wu, Zhe Wu

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Янв. 23, 2025

Background and purpose Microwave ablation (MWA) is one of the first-line therapy recommended for early-stage hepatocellular carcinoma (HCC). However, residual tumor, resulting from insufficient ablation, led to recurrence metastasis liver cancer. Novel combination strategies are urgently needed enhance efficiency MWA. Methods We detected expression XIAP protein after in primary cancer patients using immunohistochemistry. Then, we established vitro vivo IMWA models further detect expression. an model by heating HCC cell lines and, at same time, applied inhibitor AZD5582 verified proliferation, migration, pro-apoptotic ability on tumor cells CCK8, colony formation assay, scratch flow cytometry flow. The C57BL/6 NTG mice were established, was used evaluate inhibitory effects different treatment regimens growth local immune infiltration tumors. Finally, drug toxicity confirm its feasibility. Results significantly increased recurrent tissues who previously received microwave therapy. In experiments showed that migration proliferation reduced, level apoptosis application AZD5582. confirmed combined with reduced carcinoma. Concurrently, C57 BL/6 application, CD8+ T-cell increased, while Foxp3+ regulatory reduced. low through hematological pathological examinations vital organs. These results provide new clues treatment, suggesting potential role inhibitors their impact immunomodulation. Conclusions this study, found modulates microenvironment inhibits progression post-ablation

Язык: Английский

Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma DOI Creative Commons

Yau-Tuen Chan,

Cheng Zhang, Junyu Wu

и другие.

Molecular Cancer, Год журнала: 2024, Номер 23(1)

Опубликована: Сен. 6, 2024

Язык: Английский

Процитировано

38
Writers, readers, and erasers RNA modifications and drug resistance in cancer DOI Creative Commons
Di Chen, Xinyu Gu,

Yeltai Nurzat

и другие.

Molecular Cancer, Год журнала: 2024, Номер 23(1)

Опубликована: Авг. 30, 2024

Drug resistance in cancer cells significantly diminishes treatment efficacy, leading to recurrence and metastasis. A critical factor contributing this is the epigenetic alteration of gene expression via RNA modifications, such as N6-methyladenosine (m6A), N1-methyladenosine (m1A), 5-methylcytosine (m5C), 7-methylguanosine (m7G), pseudouridine (Ψ), adenosine-to-inosine (A-to-I) editing. These modifications are pivotal regulating splicing, translation, transport, degradation, stability. Governed by "writers," "readers," "erasers," impact numerous biological processes progression, including cell proliferation, stemness, autophagy, invasion, apoptosis. Aberrant can lead drug adverse outcomes various cancers. Thus, targeting modification regulators offers a promising strategy for overcoming enhancing efficacy. This review consolidates recent research on role prevalent resistance, with focus m6A, m1A, m5C, m7G, Ψ, A-to-I Additionally, it examines regulatory mechanisms linked underscores existing limitations field.

Язык: Английский

Процитировано

18
Hepatocellular carcinoma: signaling pathways and therapeutic advances DOI Creative Commons

Jiaojiao Zheng,

Siying Wang, Lei Xia

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2025, Номер 10(1)

Опубликована: Фев. 6, 2025

Abstract Liver cancer represents a major global health concern, with projections indicating that the number of new cases could surpass 1 million annually by 2025. Hepatocellular carcinoma (HCC) constitutes around 90% liver and is primarily linked to factors incluidng aflatoxin, hepatitis B (HBV) C (HCV), metabolic disorders. There are no obvious symptoms in early stage HCC, which often leads delays diagnosis. Therefore, HCC patients usually present tumors advanced incurable stages. Several signaling pathways dis-regulated cause uncontrolled cell propagation, metastasis, recurrence HCC. Beyond frequently altered therapeutically targeted receptor tyrosine kinase (RTK) involved differentiation, telomere regulation, epigenetic modification stress response also provide therapeutic potential. Investigating key their inhibitors pivotal for achieving advancements management At present, primary approaches (TKI), immune checkpoint (ICI), combination regimens. New trials investigating therapies involving ICIs TKIs or anti-VEGF (endothelial growth factor) therapies, as well combinations two immunotherapy The outcomes these expected revolutionize across all Here, we here comprehensive review cellular pathways, potential, evidence derived from late-stage clinical discuss concepts underlying earlier trials, biomarker identification, development more effective therapeutics

Язык: Английский

Процитировано

6
Role of hepatotropic viruses in promoting hepatocellular carcinoma—current knowledge and recent advances DOI

Piotr Starnawski,

Klaudia Nowak,

Zuzanna Augustyn

и другие.

Medical Oncology, Год журнала: 2025, Номер 42(4)

Опубликована: Март 17, 2025

Язык: Английский

Процитировано

1
Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway DOI Creative Commons
Hui Shao, Jingyan Chen, Ali Li

и другие.

Applied Biochemistry and Biotechnology, Год журнала: 2023, Номер 195(8), С. 5217 - 5237

Опубликована: Май 2, 2023

Abstract Salvigenin is a Trimethoxylated Flavone enriched in Scutellariae Barbatae Herba and Radix demonstrated to have anti-tumor properties colon cancer. Notwithstanding, the function mechanism of hepatocellular carcinoma (HCC) are less well studied. Different doses were taken treat HCC cells. Cell viability, colony formation ability, cell migration, invasion, apoptosis, glucose uptake, lactate production levels detected. As shown by data, concentration dependently dampened proliferation, weakened glycolysis abating uptake generation, suppressed profiles glycolytic enzymes. Moreover, strengthened cells’ sensitivity 5-fluorouracil (5-FU) attenuated 5-FU-resistant resistance 5-FU. Through network pharmacological analysis, we found potentially regulates PI3K/AKT pathway. repressed phosphorylated PI3K, AKT, GSK-3β. The PI3K activator 740Y-P induced PI3K/AKT/GSK-3β pathway activation promotive effects However, substantially 740Y-P-mediated effects. In-vivo assay revealed that hampered growth promoted apoptosis cells nude mice. Collectively, impedes aerobic 5-FU chemoresistance dampening

Язык: Английский

Процитировано

17
Kaempferol from Alpinia officinarum hance induces G2/M cell cycle arrest in hepatocellular carcinoma cells by regulating the ATM/CHEK2/KNL1 pathway DOI
Xiaoliang Li, Mingyan Zhou, Zhe Zhu

и другие.

Journal of Ethnopharmacology, Год журнала: 2024, Номер 333, С. 118430 - 118430

Опубликована: Июнь 8, 2024

Язык: Английский

Процитировано

7
Bone marrow stromal cell antigen 2: Tumor biology, signaling pathway and therapeutic targeting (Review) DOI Creative Commons
Honglian Yu,

Qiang Bian,

Xin Wang

и другие.

Oncology Reports, Год журнала: 2024, Номер 51(3)

Опубликована: Янв. 18, 2024

Bone marrow stromal cell antigen 2 (BST2) is a type II transmembrane protein that serves critical roles in antiretroviral defense the innate immune response. In addition, it has been suggested BST2 highly expressed various types of human cancer and high expression related to different clinicopathological parameters cancer. The molecular mechanism underlying as potential tumor biomarker solid tumors reported on; however, best our knowledge, there no review published on tumors. present focuses expression, structure functions; mechanisms breast cancer, hepatocellular carcinoma, gastrointestinal other tumors; therapeutic BST2; possibility marker. involved membrane integrity lipid raft formation, which can activate epidermal growth factor receptor signaling pathways, providing mechanistic link between tumorigenesis. Notably, may be considered universal therapeutical target.

Язык: Английский

Процитировано

6
The regulation of hypoxia-related lncRNAs in hepatocellular carcinoma DOI Creative Commons

Xuejing Wang,

Xiaojun Wang

Discover Oncology, Год журнала: 2024, Номер 15(1)

Опубликована: Май 7, 2024

Hepatocellular carcinoma (HCC) is still a public health disease with its high prevalence and morbidity. Short of early diagnosis biomarkers effective therapy, the treatment HCC patients hasn't achieved ideal effect. Hypoxia hallmark HCC, which mainly induced by imbalance tumor cell proliferation insufficient supply oxygen. Recently, amounting evidence suggested lncRNAs, especially hypoxia-related lncRNAs play pivotal role in regulating HCC. Hypoxia-related are involved altering glucose metabolism, maintaining cancer stem cell-like properties (CSCs), apotosis, immune escape, all contribute to poor prognosis patients. The novel identified could be potential target or beneficial clinical treatment. Herein, we summarized currently reported their related mechanisms, providing application future perspective as therapeutic target.

Язык: Английский

Процитировано

6
Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma DOI

Juan Jose Urquijo-Ponce,

Carlos Alventosa-Mateu,

Mercedes Latorre-Sánchez

и другие.

World Journal of Gastroenterology, Год журнала: 2024, Номер 30(19), С. 2512 - 2522

Опубликована: Май 17, 2024

Hepatocellular carcinoma (HCC) is a high mortality neoplasm which usually appears on cirrhotic liver. The therapeutic arsenal and subsequent prognostic outlook are intrinsically linked to the HCC stage at diagnosis. Notwithstanding current deployment of treatments with curative intent (liver resection/local ablation liver transplantation) in early intermediate stages, rate recurrence persists, underscoring pivotal clinical challenge. Emergent systemic therapies (ST), particularly immunotherapy, have demonstrate promising outcomes terms increase overall survival, but they currently bound advanced HCC. This review provides comprehensive analysis literature, encompassing studies up March 10, 2024, evaluating impact novel ST specially focusing findings neoadjuvant adjuvant regimens, aimed increasing significantly survival recurrence-free after treatment intent. We also investigate potential role enhancing downstaging for intermediate-stage initially deemed ineligible Finally, we critically discuss about relevance results these encouraging future implications schedules stages.

Язык: Английский

Процитировано

6
SLC7A11 in hepatocellular carcinoma: potential mechanisms, regulation, and clinical significance DOI Open Access
Tian-Ze Li, Jianwei Yi, Hua‐Jun Wu

и другие.

American Journal of Cancer Research, Год журнала: 2024, Номер 14(5), С. 2326 - 2342

Опубликована: Янв. 1, 2024

Exploring novel early detection biomarkers and developing more efficacious treatments remain pressing tasks in the current research landscape for hepatocellular carcinoma (HCC). Morphologically molecularly separate from apoptosis, cell death, autophagy, ferroptosis is a recently discovered, unique, controlled form of death. SLC7A11 (also known as xCT) represents subunit cystine-glutamate antiporter system Xc(-)). A growing body suggests that induction through can effectively eliminate (HCC) cells, particularly those exhibiting resistance to alternative forms Thus, targeting via may become new direction design therapeutic strategies HCC. Although many articles have investigated possible roles HCC, study summarizes main findings, including regulators mechanisms action HCC not available. Therefore, we present comprehensive overview functions ferroptosis, SLC7A11, identification, development, management this review. In addition, discuss how knowledge be translated into treatment by providing systemic therapy advanced using sorafenib, first-line drug multiple kinases SLC7A11. We further dissect barriers well corresponding solutions provide insights on navigate effective knowledge.

Язык: Английский

Процитировано

6